Liqrev, an Oral Suspension Formulation of Sildenafil, Now Available

Liqrev is a phosphodiesterase-5 (PDE-5) inhibitor that can help treat pulmonary arterial hypertension.

Liqrev® (sildenafil) Oral Suspension has been made available by CMP Pharma for patients who have difficulty swallowing sildenafil tablets.

Liqrev is indicated for the treatment of pulmonary arterial hypertension (World Health Organization Group I) in adults to improve exercise ability and delay clinical worsening. The Food and Drug Administration-approved product is expected to address dosing inconsistencies that may come from crushing or compounding sildenafil tablets.

The ready-to-use liquid is available in a strawberry flavor in 122 mL bottles. Liqrev has a 24-month shelf life.

While pediatric use is approved for Viatris Specialty LLC’s Revatio (sildenafil tablets), Liqrev is not labeled for this patient population because of marketing exclusivity rights.

This article originally appeared on MPR


1. CMP Pharma, Inc announces that Liqrev®, the first and only ready-made FDA-approved liquid suspension of sildenafil is now available. News release. June 21, 2023.
2. Liqrev. Package insert. CMP Pharma; 2023. Accessed June 22, 2023.